Amylyx initiated with a Buy at Citi

Citi analyst Geoff Meacham initiated coverage of Amylyx (AMLX) with a Buy rating and $12 price target “There is a lot to like” within the company’s pipeline, with three assets spanning four indications that range from early to late-stage studies, and several key catalysts throughout 2025 and into the first half of 2026 “that provide optionality at various timepoints,” the analyst tells investors in a research note. The firm says all four indications being pursued by Amylyx are in areas of significant high unmet need. Of the company’s ongoing Phase 2 and later studies, “clear and well-established clinical endpoints provide a direct read to probability of success and approval,” contends Citi.